The future of neonatal BCG

Area of Science:

• Immunology
• Neonatal Health
• Public Health

Background:

• Human neonates receive effective transplacental antibody transfer (IgG), unlike most mammals relying on colostrum.
• Modern birth environments often lack microbial diversity, potentially impacting infant immune system development.
• Factors like antibiotic use and C-sections bypass natural microbial exposure, influencing Th1/Th2 immune balance.

Purpose of the Study:

• To explore the potential of neonatal Bacillus Calmette-Guérin (BCG) vaccination as an adaptation strategy for contemporary human birth conditions.
• To investigate BCG's role in modulating Th1/Th2 immune responses in neonates born in low-microbial-diversity environments.
• To propose long-term randomized controlled trials evaluating BCG's impact on infant health outcomes.

Main Methods:

• Review of existing data on neonatal immune development, birth practices, and BCG effects.
• Epidemiological analysis of risk factors for autoimmune diseases, atopy, autism, and obesity in the perinatal period.
• Proposal for randomized controlled trials with 6-10 year follow-up to assess BCG's long-term health effects.

Main Results:

• Accumulating data indicate delivery mode affects Th1/Th2 immune maturation.
• Epidemiological studies link perinatal factors to increased risks of type 1 diabetes, autoimmune diseases, atopy, autism, and obesity.
• BCG vaccination is suggested as a potential modulator of these immune responses.

Conclusions:

• Neonatal BCG vaccination warrants investigation for its potential to mitigate health risks associated with modern birth environments.
• Long-term follow-up studies are ethically justified and scientifically valuable, given BCG's established safety profile and known non-specific health benefits.
• Simple adaptive practices, like maternal clothing exposure post-C-section, may offer interim support for neonatal microbial exposure.